Amneal Pharmaceuticals, Inc. ( AMRX ) revealed a new analysis of the pivotal RISE-PD Phase 3 study on Monday.
The data showed that patients who converted to Crexont from immediate release (IR) carbidopa/levodopa (CD/LD) experienced improved sleep quality.
These improvements were measured by their Parkinson’s Disease Sleep Scale-2 (PDSS-2) total scores, showing a mean difference of -2.35 (p